Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

Jamal, 2006, Cancer statistics, 2006, CA Cancer J Clin, 56, 10 Pienta, 2005, Advances in prostate cancer chemotherapy: a new era begins, CA Cancer J Clin, 55, 300, 10.3322/canjclin.55.5.300 Yagoda, 1993, Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer, Cancer, 71, 1098, 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318 Fields-Jones, 1999, Improvements in clinical benefit with vinorelbine in the treatment of hormone refractory prostate cancer: a phase II trial, Ann Oncol, 10, 1307, 10.1023/A:1008315106697 Sweeney, 2002, A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone refractory prostate cancer, Ann Oncol, 13, 435, 10.1093/annonc/mdf029 Oudard, 2001, Phase II study of vinorelbine in patients with androgen-independent prostate cancer, Ann Oncol, 12, 847, 10.1023/A:1011141611560 Kreis, 1997, Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines, Br J Urol, 79, 196, 10.1046/j.1464-410X.1997.06310.x Hainsworth, 2001, Weekly docetaxel with either gemcitabine or vinorelbine as second line treatment in patients with advanced non small cell lung carcinoma, Cancer, 92, 2391, 10.1002/1097-0142(20011101)92:9<2391::AID-CNCR1587>3.0.CO;2-M Di Lorenzo, 2004, Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer, Eur Urol, 46, 712, 10.1016/j.eururo.2004.08.022 Miller, 2000, Phase II trial of docetaxel and vinorelbine in patients with advanced non small cell lung cancer, J Clin Oncol, 18, 1346, 10.1200/JCO.2000.18.6.1346 Gravis, 2003, Weekly administration of docetaxel for symptomatic metastatic hormone refractory prostate carcinoma, Cancer, 15, 1627, 10.1002/cncr.11687 Lee, 2001, Bisphosphonate treatment inhibits the growth of prostate cancer cells, Cancer Res, 61, 2602 Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141 National Cancer Institute. Common Termination Criteria for Adverse Events, version 3.0. 2003. Cleeland, 1994, Pain assessment: global use of the Brief Pain Inventory, Ann Acad Med Singapore, 23, 129 Tong, 1982, The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group, Cancer, 50, 893, 10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9 Kaplan, 1958, Non parametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Hinsworth, 2004, Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer, J Clin Oncol, 22, 2532 Budman, 2002, Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro, Anticancer Drugs, 13, 1011, 10.1097/00001813-200211000-00005 Morant, 2002, Vinorelbine in androgen-dependent metastatic prostatic carcinoma: a phase II study, Eur J Cancer, 38, 1626, 10.1016/S0959-8049(02)00145-4 Brubaker, 2006, Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environmentm, BMC Cancer, 6, 15, 10.1186/1471-2407-6-15 Ullen, 2005, Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid, Acta Oncol, 6, 644, 10.1080/02841860510029617 Bertelli, 2006, Weekly docetaxel and zoledronic acid every 4 weeks in hormone refractory prostate cancer patients, Cancer Chemother Pharmacol, 57, 46, 10.1007/s00280-005-0025-4 Vordos, 2004, Docetaxel and zoledronic acid in patients with metastatic hormone refractory prostate cancer, BJU Int, 94, 524, 10.1111/j.1464-4096.2004.04919.x Goodin, 2005, A phase II trial of docetaxel and vinorelbine in patients with hormone refractory prostate cancer, Cancer Chemother Pharmacol, 56, 199, 10.1007/s00280-004-0980-1 Koletsky, 2003, Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone refractory prostate cancer, Cancer J, 9, 286, 10.1097/00130404-200307000-00011 Hahn, 2006, Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine and estramustine in combination in hormone refractory prostate cancer with pharmacogenetic survival analysis, Clin Cancer Res, 12, 6094, 10.1158/1078-0432.CCR-06-1188 Falsaperla, 2005, Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate, Eur Urol, 47, 449, 10.1016/j.eururo.2004.12.001 Cabrespine, 2006, Circulating chromogranin A and hormone refractory prostate cancer chemotherapy, J Urol, 175, 1347, 10.1016/S0022-5347(05)00640-3 Clarke, 2006, Management of the spectrum of the hormone refractory prostate cancer, Eur Urol, 50, 428, 10.1016/j.eururo.2006.05.017 Calabrò, 2007, Current indications for chemotherapy in prostate cancer patients, Eur Urol, 51, 17, 10.1016/j.eururo.2006.08.013